Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Ake Borg

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Genes & Molecular Sequences

Physiology

Chemicals & Drugs

Devices

Oligonucleotide Array Sequence Analysis

Geographic Areas

Sweden

Concepts & Ideas

Phenomena

Nucleic Acid Hybridization

Procedures

Fluorescence In Situ Hybridization

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
64
Olsson, Håkan
37
Fernö, Mårten
28
Johannsson, Oskar
25
Staaf, Johan
21
Baldetorp, Bo
18
Bendahl, Pär-Ola
18
Isola, Jorma
18
Loman, Niklas
17
Killander, Dick
16
Vallon-Christersson, Johan
13
Nilbert, Mef
11
Barkardottir, Rosa
11
Sandberg, Therese
10
Sellberg, Gunilla
10
Ringnér, Markus

Sign-in to see all Coauthors

Publications

TOP 3
Persson Helena; Kvist Anders; Vallon-Christersson Johan; Medstrand Patrik; Borg Ake; Rovira Carlos
The non-coding RNA of the multidrug resistance-linked vault particle encodes multiple regulatory small RNAs.
Carneiro Ana; Francis Princy; Bendahl Pär-Ola; Fernebro Josefin; Akerman Måns; Fletcher Christopher; Rydholm Anders; Borg Ake; Nilbert Mef
Indistinguishable genomic profiles and shared prognostic markers in undifferentiated pleomorphic sarcoma and leiomyosarcoma: different sides of a single coin?
Veerla Srinivas; Lindgren David; Kvist Anders; Frigyesi Attila; Staaf Johan; Persson Helena; Liedberg Fredrik; Chebil Gunilla; Gudjonsson Sigurdur; Borg Ake; Månsson Wiking; Rovira Carlos; Höglund Mattias
MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Ake Borg (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Persson Helena; Kvist Anders; Vallon-Christersson Johan; Medstrand Patrik; Borg Ake; Rovira Carlos
The non-coding RNA of the multidrug resistance-linked vault particle encodes multiple regulatory small RNAs.
Nature cell biology 2009;11(10):1268-71.
2009: Carneiro Ana; Francis Princy; Bendahl Pär-Ola; Fernebro Josefin; Akerman Måns; Fletcher Christopher; Rydholm Anders; Borg Ake; Nilbert Mef
Indistinguishable genomic profiles and shared prognostic markers in undifferentiated pleomorphic sarcoma and leiomyosarcoma: different sides of a single coin?
Laboratory investigation; a journal of technical methods and pathology 2009;89(6):668-75.
2009: Veerla Srinivas; Lindgren David; Kvist Anders; Frigyesi Attila; Staaf Johan; Persson Helena; Liedberg Fredrik; Chebil Gunilla; Gudjonsson Sigurdur; Borg Ake; Månsson Wiking; Rovira Carlos; Höglund Mattias
MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31.
International journal of cancer. Journal international du cancer 2009;124(9):2236-42.
2009: Augsten Martin; Hägglöf Christina; Olsson Eleonor; Stolz Claudia; Tsagozis Panagiotis; Levchenko Tetyana; Frederick Mitchell J; Borg Ake; Micke Patrick; Egevad Lars; Ostman Arne
CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(9):3414-9.
2009: Henriksson Eva; Kjellén Elisabeth; Baldetorp Bo; Bendahl Pär-Ola; Borg Ake; Brun Eva; Mertens Fredrik; Ohlsson Tomas; Rennstam Karin; Wennerberg Johan; Wahlberg Peter
Comparison of cisplatin sensitivity and the 18F fluoro-2-deoxy 2 glucose uptake with proliferation parameters and gene expression in squamous cell carcinoma cell lines of the head and neck.
Journal of experimental & clinical cancer research : CR 2009;28():17.
2008: Lee Jia-Jing; Au Amy Y M; Foukakis Theodoros; Barbaro Michela; Kiss Nimrod; Clifton-Bligh Roderick; Staaf Johan; Borg Ake; Delbridge Leigh; Robinson Bruce G; Wallin Göran; Höög Anders; Larsson Catharina
Array-CGH identifies cyclin D1 and UBCH10 amplicons in anaplastic thyroid carcinoma.
Endocrine-related cancer 2008;15(3):801-15.
2008: Gunnarsson Rebeqa; Staaf Johan; Jansson Mattias; Ottesen Anne Marie; Göransson Hanna; Liljedahl Ulrika; Ralfkiaer Ulrik; Mansouri Mahmoud; Buhl Anne Mette; Smedby Karin Ekström; Hjalgrim Henrik; Syvänen Ann-Christine; Borg Ake; Isaksson Anders; Jurlander Jesper; Juliusson Gunnar; Rosenquist Richard
Screening for copy-number alterations and loss of heterozygosity in chronic lymphocytic leukemia--a comparative study of four differently designed, high resolution microarray platforms.
Genes, chromosomes & cancer 2008;47(8):697-711.
2008: Staaf Johan; Törngren Therese; Rambech Eva; Johansson Ulla; Persson Camilla; Sellberg Gunilla; Tellhed Lina; Nilbert Mef; Borg Ake
Detection and precise mapping of germline rearrangements in BRCA1, BRCA2, MSH2, and MLH1 using zoom-in array comparative genomic hybridization (aCGH).
Human mutation 2008;29(4):555-64.
2008: Kuchinskaya Ekaterina; Heyman Mats; Nordgren Ann; Schoumans Jacqueline; Staaf Johan; Borg Ake; Söderhäll Stefan; Grandér Dan; Nordenskjöld Magnus; Blennow Elisabeth
Array-CGH reveals hidden gene dose changes in children with acute lymphoblastic leukaemia and a normal or failed karyotype by G-banding.
British journal of haematology 2008;140(5):572-7.
2008: Nielsen K; Masback A; Bladstrom A; Lundgren L; Jonsson N; Borg A; Ingvar C; Olsson H
Confirmed cancer trends in families of patients with multiple cancers including cutaneous melanoma.
The British journal of dermatology 2008;158(2):429-31.
2008: Osoegawa K; Vessere G M; Utami K H; Mansilla M A; Johnson M K; Riley B M; L'Heureux J; Pfundt R; Staaf J; van der Vliet W A; Lidral A C; Schoenmakers E F P M; Borg A; Schutte B C; Lammer E J; Murray J C; de Jong P J
Identification of novel candidate genes associated with cleft lip and palate using array comparative genomic hybridisation.
Journal of medical genetics 2008;45(2):81-6.
2008: Ratajska Magdalena; Brozek Izabela; Senkus-Konefka Elzbieta; Jassem Jacek; Stepnowska Magdalena; Palomba Grazia; Pisano Marina; Casula Milena; Palmieri Giuseppe; Borg Ake; Limon Janusz
BRCA1 and BRCA2 point mutations and large rearrangements in breast and ovarian cancer families in Northern Poland.
Oncology reports 2008;19(1):263-8.
2008: Saal Lao H; Gruvberger-Saal Sofia K; Persson Camilla; Lövgren Kristina; Jumppanen Mervi; Staaf Johan; Jönsson Göran; Pires Maira M; Maurer Matthew; Holm Karolina; Koujak Susan; Subramaniyam Shivakumar; Vallon-Christersson Johan; Olsson Håkan; Su Tao; Memeo Lorenzo; Ludwig Thomas; Ethier Stephen P; Krogh Morten; Szabolcs Matthias; Murty Vundavalli V V S; Isola Jorma; Hibshoosh Hanina; Parsons Ramon; Borg Ake
Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair.
Nature genetics 2008;40(1):102-7.
2008: Fernebro Josefin; Carneiro Ana; Rydholm Anders; Domanski Henryk A; Karlsson Anna; Borg Ake; Nilbert Mef
Genetic profiling differentiates second primary tumors from metastases in adult metachronous soft tissue sarcoma.
Sarcoma 2008;2008():431019.
2008: Staaf Johan; Vallon-Christersson Johan; Lindgren David; Juliusson Gunnar; Rosenquist Richard; Höglund Mattias; Borg Ake; Ringnér Markus
Normalization of Illumina Infinium whole-genome SNP data improves copy number estimates and allelic intensity ratios.
BMC bioinformatics 2008;9():409.
2008: Staaf Johan; Lindgren David; Vallon-Christersson Johan; Isaksson Anders; Göransson Hanna; Juliusson Gunnar; Rosenquist Richard; Höglund Mattias; Borg Ake; Ringnér Markus
Segmentation-based detection of allelic imbalance and loss-of-heterozygosity in cancer cells using whole genome SNP arrays.
Genome biology 2008;9(9):R136.
2008: Lindgren David; Gudjonsson Sigurdur; Jee Kowan Ja; Liedberg Fredrik; Aits Sonja; Andersson Anna; Chebil Gunilla; Borg Ake; Knuutila Sakari; Fioretos Thoas; Månsson Wiking; Höglund Mattias
Recurrent and multiple bladder tumors show conserved expression profiles.
BMC cancer 2008;8():183.
2008: Honeth Gabriella; Bendahl Pär-Ola; Ringnér Markus; Saal Lao H; Gruvberger-Saal Sofia K; Lövgren Kristina; Grabau Dorthe; Fernö Mårten; Borg Ake; Hegardt Cecilia
The CD44+/CD24- phenotype is enriched in basal-like breast tumors.
Breast cancer research : BCR 2008;10(3):R53.
2008: Thomassen Mads; Hansen Thomas V O; Borg Ake; Lianee Henriette Theilmann; Wikman Friedrik; Pedersen Inge Søkilde; Bisgaard Marie Luise; Nielsen Finn C; Kruse Torben A; Gerdes Anne-Marie
BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer.
Acta oncologica (Stockholm, Sweden) 2008;47(4):772-7.
2008: Heidenblad Markus; Lindgren David; Jonson Tord; Liedberg Fredrik; Veerla Srinivas; Chebil Gunilla; Gudjonsson Sigurdur; Borg Ake; Månsson Wiking; Höglund Mattias
Tiling resolution array CGH and high density expression profiling of urothelial carcinomas delineate genomic amplicons and candidate target genes specific for advanced tumors.
BMC medical genomics 2008;1():3.
2007: Persson Oscar; Krogh Morten; Saal Lao H; Englund Elisabet; Liu Jian; Parsons Ramon; Mandahl Nils; Borg Ake; Widegren Bengt; Salford Leif G
Microarray analysis of gliomas reveals chromosomal position-associated gene expression patterns and identifies potential immunotherapy targets.
Journal of neuro-oncology 2007;85(1):11-24.
2007: Huang Jian; Gusnanto Arief; O'Sullivan Kathleen; Staaf Johan; Borg Ake; Pawitan Yudi
Robust smooth segmentation approach for array CGH data analysis.
Bioinformatics (Oxford, England) 2007;23(18):2463-9.
2007: Davidsson Josef; Andersson Anna; Paulsson Kajsa; Heidenblad Markus; Isaksson Margareth; Borg Ake; Heldrup Jesper; Behrendtz Mikael; Panagopoulos Ioannis; Fioretos Thoas; Johansson Bertil
Tiling resolution array comparative genomic hybridization, expression and methylation analyses of dup(1q) in Burkitt lymphomas and pediatric high hyperdiploid acute lymphoblastic leukemias reveal clustered near-centromeric breakpoints and overexpression of genes in 1q22-32.3.
Human molecular genetics 2007;16(18):2215-25.
2007: Svensson Emelie; Vidovic Karina; Olofsson Tor; Vallon-Christersson Johan; Borg Ake; Gullberg Urban
The Wilms' tumor gene 1 (WT1) induces expression of the N-myc downstream regulated gene 2 (NDRG2).
DNA and cell biology 2007;26(8):589-97.
2007: Jönsson G; Dahl C; Staaf J; Sandberg T; Bendahl P-O; Ringnér M; Guldberg P; Borg A
Genomic profiling of malignant melanoma using tiling-resolution arrayCGH.
Oncogene 2007;26(32):4738-48.
2007: Jönsson Göran; Staaf Johan; Olsson Eleonor; Heidenblad Markus; Vallon-Christersson Johan; Osoegawa Kazutoyo; de Jong Pieter; Oredsson Stina; Ringnér Markus; Höglund Mattias; Borg Ake
High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization.
Genes, chromosomes & cancer 2007;46(6):543-58.
2007: Kuchinskaya E; Nordgren A; Heyman M; Schoumans J; Corcoran M; Staaf J; Borg A; Söderhäll S; Grandér D; Nordenskjöld M; Blennow E
Tiling-resolution array-CGH reveals the pattern of DNA copy number alterations in acute lymphoblastic leukemia with 21q amplification: the result of telomere dysfunction and breakage/fusion/breakage cycles?
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(6):1327-30.
2007: Saal Lao H; Johansson Peter; Holm Karolina; Gruvberger-Saal Sofia K; She Qing-Bai; Maurer Matthew; Koujak Susan; Ferrando Adolfo A; Malmström Per; Memeo Lorenzo; Isola Jorma; Bendahl Pär-Ola; Rosen Neal; Hibshoosh Hanina; Ringnér Markus; Borg Ake; Parsons Ramon
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(18):7564-9.
2007: Balciuniene Jorune; Feng Ningping; Iyadurai Kelly; Hirsch Betsy; Charnas Lawrence; Bill Brent R; Easterday Mathew C; Staaf Johan; Oseth LeAnn; Czapansky-Beilman Desiree; Avramopoulos Dimitri; Thomas George H; Borg Ake; Valle David; Schimmenti Lisa A; Selleck Scott B
Recurrent 10q22-q23 deletions: a genomic disorder on 10q associated with cognitive and behavioral abnormalities.
American journal of human genetics 2007;80(5):938-47.
2007: Gustavsson Peter; Schoumans Jacqueline; Staaf Johan; Borg Ake; Nordenskjöld Magnus; Annerén Göran
Duplication 16q12.1-q22.1 characterized by array CGH in a girl with spina bifida.
European journal of medical genetics 2007;50(3):237-41.
2007: Gruvberger-Saal Sofia K; Bendahl Pär-Ola; Saal Lao H; Laakso Mervi; Hegardt Cecilia; Edén Patrik; Peterson Carsten; Malmström Per; Isola Jorma; Borg Ake; Fernö Mårten
Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(7):1987-94.
2007: Henningson M; Johansson U; Borg A; Olsson H; Jernström Helena
CYP17 genotype is associated with short menstrual cycles, early oral contraceptive use and BRCA mutation status in young healthy women.
Molecular human reproduction 2007;13(4):231-6.
2007: Schoumans Jacqueline; Wincent Josephine; Barbaro Michela; Djureinovic Tatjana; Maguire Paula; Forsberg Lena; Staaf Johan; Thuresson Ann Charlotte; Borg Ake; Nordgren Ann; Malm Gunilla; Anderlid Britt Marie
Comprehensive mutational analysis of a cohort of Swedish Cornelia de Lange syndrome patients.
European journal of human genetics : EJHG 2007;15(2):143-9.
2007: Rennstam Karin; Jönsson Göran; Tanner Minna; Bendahl Pär-Ola; Staaf Johan; Kapanen Anita I; Karhu Ritva; Baldetorp Bo; Borg Ake; Isola Jorma
Cytogenetic characterization and gene expression profiling of the trastuzumab-resistant breast cancer cell line JIMT-1.
Cancer genetics and cytogenetics 2007;172(2):95-106.
2007: Hietala M; Sandberg T; Borg A; Olsson H; Jernström H
Testosterone levels in relation to oral contraceptive use and the androgen receptor CAG and GGC length polymorphisms in healthy young women.
Human reproduction (Oxford, England) 2007;22(1):83-91.
2007: Lundin C; Heidenblad M; Strombeck B; Borg A; Hovland R; Heim S; Johansson B
Tiling resolution array CGH of dic(7;9)(p11 approximately 13;p11 approximately 13) in B-cell precursor acute lymphoblastic leukemia reveals clustered breakpoints at 7p11.2 approximately 12.1 and 9p13.1.
Cytogenetic and genome research 2007;118(1):13-8.
2007: Vallon-Christersson Johan; Staaf Johan; Kvist Anders; Medstrand Patrik; Borg Ake; Rovira Carlos
Non-coding antisense transcription detected by conventional and single-stranded cDNA microarray.
BMC genomics 2007;8():295.
2007: Henningson Maria; Bågeman Erika; Sandberg Therese; Borg Ake; Olsson Håkan; Jernström Helena
Absence of the common IGF1 19 CA-repeat allele is more common among BRCA1 mutation carriers than among non-carriers from BRCA1 families.
Familial cancer 2007;6(4):445-52.
2007: Jumppanen Mervi; Gruvberger-Saal Sofia; Kauraniemi Päivikki; Tanner Minna; Bendahl Pär-Ola; Lundin Mikael; Krogh Morten; Kataja Pasi; Borg Ake; Fernö Mårten; Isola Jorma
Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers.
Breast cancer research : BCR 2007;9(1):R16.
2006: Holmquist-Mengelbier Linda; Fredlund Erik; Löfstedt Tobias; Noguera Rosa; Navarro Samuel; Nilsson Helén; Pietras Alexander; Vallon-Christersson Johan; Borg Ake; Gradin Katarina; Poellinger Lorenz; Påhlman Sven
Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype.
Cancer cell 2006;10(5):413-23.
2006: Schoumans Jacqueline; Johansson Bertil; Corcoran Martin; Kuchinskaya Ekaterina; Golovleva Irina; Grandér Dan; Forestier Erik; Staaf Johan; Borg Ake; Gustafsson Britt; Blennow Elisabeth; Nordgren Ann
Characterisation of dic(9;20)(p11-13;q11) in childhood B-cell precursor acute lymphoblastic leukaemia by tiling resolution array-based comparative genomic hybridisation reveals clustered breakpoints at 9p13.2 and 20q11.2.
British journal of haematology 2006;135(4):492-9.
2006: Paulsson K; Heidenblad M; Mörse H; Borg A; Fioretos T; Johansson B
Identification of cryptic aberrations and characterization of translocation breakpoints using array CGH in high hyperdiploid childhood acute lymphoblastic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2006;20(11):2002-7.
2006: Karppinen S-M; Barkardottir R B; Backenhorn K; Sydenham T; Syrjäkoski K; Schleutker J; Ikonen T; Pylkäs K; Rapakko K; Erkko H; Johannesdottir G; Gerdes A-M; Thomassen M; Agnarsson B A; Grip M; Kallioniemi A; Kere J; Aaltonen L A; Arason A; Møller P; Kruse T A; Borg A; Winqvist R
Nordic collaborative study of the BARD1 Cys557Ser allele in 3956 patients with cancer: enrichment in familial BRCA1/BRCA2 mutation-negative breast cancer but not in other malignancies.
Journal of medical genetics 2006;43(11):856-62.
2006: Heidenblad M; Hallor K H; Staaf J; Jönsson G; Borg A; Höglund M; Mertens F; Mandahl N
Genomic profiling of bone and soft tissue tumors with supernumerary ring chromosomes using tiling resolution bacterial artificial chromosome microarrays.
Oncogene 2006;25(53):7106-16.
2006: Davidsson Josef; Heidenblad Markus; Borg Ake; Johansson Bertil
Array-based comparative genomic hybridization characterization of cytogenetically polyclonal myeloid malignancies.
Cancer genetics and cytogenetics 2006;169(2):179-80.
2006: Johannsdottir Hrefna K; Jonsson Goran; Johannesdottir Gudrun; Agnarsson Bjarni A; Eerola Hannaleena; Arason Adalgeir; Heikkila Paivi; Egilsson Valgardur; Olsson Hakan; Johannsson Oskar Th; Nevanlinna Heli; Borg Ake; Barkardottir Rosa B
Chromosome 5 imbalance mapping in breast tumors from BRCA1 and BRCA2 mutation carriers and sporadic breast tumors.
International journal of cancer. Journal international du cancer 2006;119(5):1052-60.
2006: Heikkinen Katri; Rapakko Katrin; Karppinen Sanna-Maria; Erkko Hannele; Knuutila Sakari; Lundán Tuija; Mannermaa Arto; Børresen-Dale Anne-Lise; Borg Ake; Barkardottir Rosa B; Petrini John; Winqvist Robert
RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability.
Carcinogenesis 2006;27(8):1593-9.
2006: Jernström Helena; Sellberg Gunilla; Borg Ake; Olsson Hakan
Differences in IGFBP-3 regulation between young healthy women from BRCAX families and those belonging to BRCA1/2 families.
European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 2006;15(3):233-41.
2006: Gustavsson P; Schoumans J; Staaf J; Jönsson G; Carlsson F; Kristoffersson U; Borg A; Nordenskjöld M; Dahl N
Hemizygosity for chromosome 2q14.2-q22.1 spanning the GLI2 and PROC genes associated with growth hormone deficiency, polydactyly, deep vein thrombosis and urogenital abnormalities.
Clinical genetics 2006;69(5):441-3.
2006: Paulsson K; Heidenblad M; Strömbeck B; Staaf J; Jönsson G; Borg A; Fioretos T; Johansson B
High-resolution genome-wide array-based comparative genome hybridization reveals cryptic chromosome changes in AML and MDS cases with trisomy 8 as the sole cytogenetic aberration.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2006;20(5):840-6.
2006: Malander Susanne; Rambech Eva; Kristoffersson Ulf; Halvarsson Britta; Ridderheim Mona; Borg Ake; Nilbert Mef
The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer.
Gynecologic oncology 2006;101(2):238-43.
2006: Lindgren D; Liedberg F; Andersson A; Chebil G; Gudjonsson S; Borg A; Månsson W; Fioretos T; Höglund M
Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q.
Oncogene 2006;25(18):2685-96.
2006: Szymanowska Amelia; Jassem Ewa; Dziadziuszko Rafal; Borg Ake; Limon Janusz; Kobierska-Gulida Grazyna; Rzyman Witold; Jassem Jacek
Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism.
Lung cancer (Amsterdam, Netherlands) 2006;52(1):9-14.
2006: Fernebro Josefin; Francis Princy; Edén Patrik; Borg Ake; Panagopoulos Ioannis; Mertens Fredrik; Vallon-Christersson Johan; Akerman Måns; Rydholm Anders; Bauer Henrik C F; Mandahl Nils; Nilbert Mef
Gene expression profiles relate to SS18/SSX fusion type in synovial sarcoma.
International journal of cancer. Journal international du cancer 2006;118(5):1165-72.
2006: Jernström H; Sandberg T; Bågeman E; Borg A; Olsson H
Insulin-like growth factor-1 genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating insulin-like growth factor-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2006;16 Suppl 2():497.
2006: Henriksson Eva; Baldetorp Bo; Borg Ake; Kjellen Elisabeth; Akervall Jan; Wennerberg Johan; Wahlberg Peter
p53 mutation and cyclin D1 amplification correlate with cisplatin sensitivity in xenografted human squamous cell carcinomas from head and neck.
Acta oncologica (Stockholm, Sweden) 2006;45(3):300-5.
2006: Isinger Anna; Bhat Misha; Borg Ake; Nilbert Mef
CHEK2 1100delC in patients with metachronous cancers of the breast and the colorectum.
BMC cancer 2006;6():64.
2005: Jernström Helena; Loman Niklas; Johannsson Oskar T; Borg Ake; Olsson Håkan
Impact of teenage oral contraceptive use in a population-based series of early-onset breast cancer cases who have undergone BRCA mutation testing.
European journal of cancer (Oxford, England : 1990) 2005;41(15):2312-20.
2005: Laakso Mervi; Loman Niklas; Borg Ake; Isola Jorma
Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2005;18(10):1321-8.
2005: Jönsson Göran; Bendahl Pär-Ola; Sandberg Therese; Kurbasic Azra; Staaf Johan; Sunde Lone; Crüger Dorthe G; Ingvar Christian; Olsson Håkan; Borg Ake
Mapping of a novel ocular and cutaneous malignant melanoma susceptibility locus to chromosome 9q21.32.
Journal of the National Cancer Institute 2005;97(18):1377-82.
2005: Jönsson Göran; Naylor Tara L; Vallon-Christersson Johan; Staaf Johan; Huang Jia; Ward M Renee; Greshock Joel D; Luts Lena; Olsson Håkan; Rahman Nazneen; Stratton Michael; Ringnér Markus; Borg Ake; Weber Barbara L
Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization.
Cancer research 2005;65(17):7612-21.
2005: Schoumans Jacqueline; Staaf Johan; Jönsson Göran; Rantala Johanna; Zimmer Kerstin Sars; Borg Ake; Nordenskjöld Magnus; Anderlid Britt-Marie
Detection and delineation of an unusual 17p11.2 deletion by array-CGH and refinement of the Smith-Magenis syndrome minimum deletion to approximately 650 kb.
European journal of medical genetics 2005;48(3):290-300.
2005: Francis Princy; Fernebro Josefin; Edén Patrik; Laurell Anna; Rydholm Anders; Domanski Henryk A; Breslin Thomas; Hegardt Cecilia; Borg Ake; Nilbert Mef
Intratumor versus intertumor heterogeneity in gene expression profiles of soft-tissue sarcomas.
Genes, chromosomes & cancer 2005;43(3):302-8.
2005: Andersson A; Edén P; Lindgren D; Nilsson J; Lassen C; Heldrup J; Fontes M; Borg A; Mitelman F; Johansson B; Höglund M; Fioretos T
Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(6):1042-50.
2005: Saal Lao H; Holm Karolina; Maurer Matthew; Memeo Lorenzo; Su Tao; Wang Xiaomei; Yu Jennifer S; Malmström Per-Olof; Mansukhani Mahesh; Enoksson Jens; Hibshoosh Hanina; Borg Ake; Parsons Ramon
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.
Cancer research 2005;65(7):2554-9.
2005: Kvist Anders; Rovira Carlos; Borg Ake; Medstrand Patrik
Promoter usage of BRCA1-IRIS.
Nature cell biology 2005;7(4):325-6; author rply 326.
2005: Jernström H; Sandberg T; Bågeman E; Borg A; Olsson H
Insulin-like growth factor-1 (IGF1) genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating IGF-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families.
British journal of cancer 2005;92(5):857-66.
2005: Szymanowska Amelia; Jassem Ewa; Dziadziuszko Rafal; Skrzypski Marcin; Kobierska-Gulida Grazyna; Holm Karolina; Borg Ake; Rzyman Witold; Limon Janusz; Jassem Jacek
[Analysis of prognostic value of TP53 gene mutations in non-small cell lung cancer]
Pneumonologia i alergologia polska : organ Polskiego Towarzystwa Ftyzjopneumonologicznego, Polskiego Towarzystwa Alergologicznego, i Instytutu Gruzlicy i Chorób Pluc 2005;73(3):264-9.
2004: Thomassen Mads; Kruse Torben A; Olsen Karen Ege; Borg A; Gerdes Anne Marie
Loss of heterozygosity at BRCA2 in a ductal carcinoma in situ and three invasive breast carcinomas in a family with a germline BRCA2 mutation.
Breast cancer research and treatment 2004;87(3):273-6.
2004: Syrjäkoski Kirsi; Kuukasjärvi Tuula; Waltering Kati; Haraldsson Karin; Auvinen Anssi; Borg Ake; Kainu Tommi; Kallioniemi Olli-P; Koivisto Pasi A
BRCA2 mutations in 154 finnish male breast cancer patients.
Neoplasia (New York, N.Y.) 2004;6(5):541-5.
2004: Johannsdottir Hrefna K; Johannesdottir Gudrun; Agnarsson Bjarni A; Eerola Hannaleena; Arason Adalgeir; Johannsson Oskar T H; Heikkilä Päivi; Egilsson Valgardur; Olsson Hakan; Borg Ake; Nevanlinna Heli; Barkardottir Rosa B
Deletions on chromosome 4 in sporadic and BRCA mutated tumors and association with pathological variables.
Anticancer research 2004;24(5A):2681-7.
2004: Jögi Annika; Vallon-Christersson Johan; Holmquist Linda; Axelson Håkan; Borg Ake; Påhlman Sven
Human neuroblastoma cells exposed to hypoxia: induction of genes associated with growth, survival, and aggressive behavior.
Experimental cell research 2004;295(2):469-87.
2004: Obad Susanna; Brunnström Hans; Vallon-Christersson Johan; Borg Ake; Drott Kristina; Gullberg Urban
Staf50 is a novel p53 target gene conferring reduced clonogenic growth of leukemic U-937 cells.
Oncogene 2004;23(23):4050-9.
2004: Nielsen K; Ingvar C; Måsbäck A; Westerdahl J; Borg A; Sandberg T; Jonsson N; Nagel J; Olsson H
Melanoma and nonmelanoma skin cancer in patients with multiple tumours--evidence for new syndromes in a population-based study.
The British journal of dermatology 2004;150(3):531-6.
2004: Gruvberger-Saal Sofia K; Edén Patrik; Ringnér Markus; Baldetorp Bo; Chebil Gunilla; Borg Ake; Fernö Mårten; Peterson Carsten; Meltzer Paul S
Predicting continuous values of prognostic markers in breast cancer from microarray gene expression profiles.
Molecular cancer therapeutics 2004;3(2):161-8.
2004: Malander S; Ridderheim M; Måsbäck A; Loman N; Kristoffersson U; Olsson H; Nilbert M; Borg A
One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden.
European journal of cancer (Oxford, England : 1990) 2004;40(3):422-8.
2003: Rennstam Karin; Ahlstedt-Soini Minna; Baldetorp Bo; Bendahl Pär-Ola; Borg Ake; Karhu Ritva; Tanner Minna; Tirkkonen Mika; Isola Jorma
Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis. A study of 305 tumors by comparative genomic hybridization.
Cancer research 2003;63(24):8861-8.
2003: Krop Ian; Maguire Paula; Lahti-Domenici Jaana; Lodeiro Gabriela; Richardson Andrea; Johannsdottir Hrefna Kristin; Nevanlinna Heli; Borg Ake; Gelman Rebecca; Barkardottir Rosa Björk; Lindblom Annika; Polyak Kornelia
Lack of HIN-1 methylation in BRCA1-linked and "BRCA1-like" breast tumors.
Cancer research 2003;63(9):2024-7.
2003: Perkowska Magdalena; BroZek Izabela; Wysocka Barbara; Haraldsson Karin; Sandberg Therese; Johansson Ulla; Sellberg Gunilla; Borg Ake; Limon Janusz
BRCA1 and BRCA2 mutation analysis in breast-ovarian cancer families from northeastern Poland.
Human mutation 2003;21(5):553-4.
2003: Johannsson Oskar T; Staff Synnöve; Vallon-Christersson Johan; Kytöla Soili; Gudjonsson Thorarinn; Rennstam Karin; Hedenfalk Ingrid A; Adeyinka Adewale; Kjellén Elisabeth; Wennerberg Johan; Baldetorp Bo; Petersen Ole W; Olsson Håkan; Oredsson Stina; Isola Jorma; Borg Ake
Characterization of a novel breast carcinoma xenograft and cell line derived from a BRCA1 germ-line mutation carrier.
Laboratory investigation; a journal of technical methods and pathology 2003;83(3):387-96.
2003: Hedenfalk Ingrid; Ringner Markus; Ben-Dor Amir; Yakhini Zohar; Chen Yidong; Chebil Gunilla; Ach Robert; Loman Niklas; Olsson Håkan; Meltzer Paul; Borg Ake; Trent Jeffrey
Molecular classification of familial non-BRCA1/BRCA2 breast cancer.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(5):2532-7.
2003: Loman Niklas; Bladström Anna; Johannsson Oskar; Borg Ake; Olsson Håkan
Cancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known BRCA1 and BRCA2 mutation status.
Breast cancer research : BCR 2003;5(6):R175-86.
2003: Gruvberger Sofia K; Ringnér Markus; Edén Patrik; Borg Ake; Fernö Mårten; Peterson Carsten; Meltzer Paul S
Expression profiling to predict outcome in breast cancer: the influence of sample selection.
Breast cancer research : BCR 2003;5(1):23-6.
2002: Måsbäck A; Olsson H; Westerdahl J; Sandberg T; Borg A; Jonsson N; Ingvar C
Clinical and histopathological features of malignant melanoma in germline CDKN2A mutation families.
Melanoma research 2002;12(6):549-57.
2002: Møller Pål; Borg Ake; Evans D Gareth; Haites Neva; Reis Marta M; Vasen Hans; Anderson Elaine; Steel C Michael; Apold Jaran; Goudie David; Howell Anthony; Lalloo Fiona; Maehle Lovise; Gregory Helen; Heimdal Ketil
Survival in prospectively ascertained familial breast cancer: analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy.
International journal of cancer. Journal international du cancer 2002;101(6):555-9.
2002: Worley Terri; Vallon-Christersson Johan; Billack Blase; Borg Ake; Monteiro Alvaro N A
A naturally occurring allele of BRCA1 coding for a temperature-sensitive mutant protein.
Cancer biology & therapy 2002;1(5):497-501.
2002: Saal Lao H; Troein Carl; Vallon-Christersson Johan; Gruvberger Sofia; Borg Ake; Peterson Carsten
BioArray Software Environment (BASE): a platform for comprehensive management and analysis of microarray data.
Genome biology 2002;3(8):SOFTWARE0003.
2002: Koul Anjila; Bendahl P-O; Borg A; Fernö M; Lidebring M F; Högberg T; Einarsson E L; Ridderheim M; Willén R
TP53 protein expression analysis by luminometric immunoassay in comparison with gene mutation status and prognostic factors in early stage endometrial cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2002;12(4):362-71.
2002: Koul Anjila; Willén Roger; Bendahl Pär-Ola; Nilbert Mef; Borg Ake
Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis.
Cancer 2002;94(9):2369-79.
2002: Rozenblum Ester; Vahteristo Pia; Sandberg Therese; Bergthorsson Jon Thor; Syrjakoski Kirsi; Weaver Don; Haraldsson Karin; Johannsdottir Hrefna Kristin; Vehmanen Paula; Nigam Savita; Golberger Natalie; Robbins Christiane; Pak Evgenia; Dutra Amalia; Gillander Elizabeth; Stephan Dietrich A; Bailey-Wilson Joan; Juo Suh-Hang Hank; Kainu Tommi; Arason Adalgeir; Barkardottir Rosa Bjork; Nevanlinna Heli; Borg Ake; Kallioniemi Olli-P
A genomic map of a 6-Mb region at 13q21-q22 implicated in cancer development: identification and characterization of candidate genes.
Human genetics 2002;110(2):111-21.
2002: Akervall Jan; Borg Ake; Dictor Michael; Jin Charlotte; Jin Yuesheng; Tanner Minna; Isola Jorma; Mertens Fredrik; Wennerberg Johan
Chromosomal translocations involving 11q13 contribute to cyclin D1 overexpression in squamous cell carcinoma of the head and neck.
International journal of oncology 2002;20(1):45-52.
2002: Hedenfalk Ingrid A; Ringnér Markus; Trent Jeffrey M; Borg Ake
Gene expression in inherited breast cancer.
Advances in cancer research 2002;84():1-34.
2001: Møller P; Heimdal K; Apold J; Fredriksen A; Borg A; Hovig E; Hagen A; Hagen B; Pedersen J C; Maehle L;
Genetic epidemiology of BRCA1 mutations in Norway.
European journal of cancer (Oxford, England : 1990) 2001;37(18):2428-34.
2001: Staff S; Isola J J; Johannsson O; Borg A; Tanner M M
Frequent somatic loss of BRCA1 in breast tumours from BRCA2 germ-line mutation carriers and vice versa.
British journal of cancer 2001;85(8):1201-5.
2001: Loman N; Johannsson O; Kristoffersson U; Olsson H; Borg A
Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer.
Journal of the National Cancer Institute 2001;93(16):1215-23.
2001: Bergthorsson J T; Ejlertsen B; Olsen J H; Borg A; Nielsen K V; Barkardottir R B; Klausen S; Mouridsen H T; Winther K; Fenger K; Niebuhr A; Harboe T L; Niebuhr E
BRCA1 and BRCA2 mutation status and cancer family history of Danish women affected with multifocal or bilateral breast cancer at a young age.
Journal of medical genetics 2001;38(6):361-8.
2001: Hashemi J; Bendahl P O; Sandberg T; Platz A; Linder S; Stierner U; Olsson H; Ingvar C; Hansson J; Borg A
Haplotype analysis and age estimation of the 113insR CDKN2A founder mutation in Swedish melanoma families.
Genes, chromosomes & cancer 2001;31(2):107-16.
2001: Møller P; Borg A; Heimdal K; Apold J; Vallon-Christersson J; Hovig E; Maehle L;
The BRCA1 syndrome and other inherited breast or breast-ovarian cancers in a Norwegian prospective series.
European journal of cancer (Oxford, England : 1990) 2001;37(8):1027-32.
2001: Koul A; Loman N; Malander S; Borg A; Ridderheim M
Two BRCA1-positive epithelial ovarian tumors with metastases to the central nervous system: a case report.
Gynecologic oncology 2001;80(3):399-402.
2001: Hedenfalk I; Duggan D; Chen Y; Radmacher M; Bittner M; Simon R; Meltzer P; Gusterson B; Esteller M; Kallioniemi O P; Wilfond B; Borg A; Trent J; Raffeld M; Yakhini Z; Ben-Dor A; Dougherty E; Kononen J; Bubendorf L; Fehrle W; Pittaluga S; Gruvberger S; Loman N; Johannsson O; Olsson H; Sauter G
Gene-expression profiles in hereditary breast cancer.
The New England journal of medicine 2001;344(8):539-48.
2001: Vallon-Christersson J; Cayanan C; Haraldsson K; Loman N; Bergthorsson J T; Brøndum-Nielsen K; Gerdes A M; Møller P; Kristoffersson U; Olsson H; Borg A; Monteiro A N
Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families.
Human molecular genetics 2001;10(4):353-60.
2001: Salahshor S; Haixin L; Huo H; Kristensen V N; Loman N; Sjöberg-Margolin S; Borg A; Børresen-Dale A L; Vorechovsky I; Lindblom A
Low frequency of E-cadherin alterations in familial breast cancer.
Breast cancer research : BCR 2001;3(3):199-207.
2000: Sarantaus L; Huusko P; Eerola H; Launonen V; Vehmanen P; Rapakko K; Gillanders E; Syrjäkoski K; Kainu T; Vahteristo P; Krahe R; Pääkkönen K; Hartikainen J; Blomqvist C; Löppönen T; Holli K; Ryynänen M; Bützow R; Borg A; Wasteson Arver B; Holmberg E; Mannermaa A; Kere J; Kallioniemi O P; Winqvist R; Nevanlinna H
Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland.
European journal of human genetics : EJHG 2000;8(10):757-63.
2000: Kauraniemi P; Hedenfalk I; Persson K; Duggan D J; Tanner M; Johannsson O; Olsson H; Trent J M; Isola J; Borg A
MYB oncogene amplification in hereditary BRCA1 breast cancer.
Cancer research 2000;60(19):5323-8.
2000: Mineta H; Miura K; Ogino T; Takebayashi S; Misawa K; Ueda Y; Suzuki I; Dictor M; Borg A; Wennerberg J
Prognostic value of vascular endothelial growth factor (VEGF) in head and neck squamous cell carcinomas.
British journal of cancer 2000;83(6):775-81.
2000: Planck M; Wenngren E; Borg A; Olsson H; Nilbert M
Somatic frameshift alterations in mononucleotide repeat-containing genes in different tumor types from an HNPCC family with germline MSH2 mutation.
Genes, chromosomes & cancer 2000;29(1):33-9.
2000: Borg A; Sandberg T; Nilsson K; Johannsson O; Klinker M; Måsbäck A; Westerdahl J; Olsson H; Ingvar C
High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families.
Journal of the National Cancer Institute 2000;92(15):1260-6.
2000: Staff S; Nupponen N N; Borg A; Isola J J; Tanner M M
Multiple copies of mutant BRCA1 and BRCA2 alleles in breast tumors from germ-line mutation carriers.
Genes, chromosomes & cancer 2000;28(4):432-42.
2000: Loman N; Johannsson O; Bendahl P; Dahl N; Einbeigi Z; Gerdes A; Borg A; Olsson H
Prognosis and clinical presentation of BRCA2-associated breast cancer.
European journal of cancer (Oxford, England : 1990) 2000;36(11):1365-73.
2000: Tanner M M; Grenman S; Koul A; Johannsson O; Meltzer P; Pejovic T; Borg A; Isola J J
Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(5):1833-9.
2000: Adeyinka A; Mertens F; Bondeson L; Garne J P; Borg A; Baldetorp B; Pandis N
Cytogenetic heterogeneity and clonal evolution in synchronous bilateral breast carcinomas and their lymph node metastases from a male patient without any detectable BRCA2 germline mutation.
Cancer genetics and cytogenetics 2000;118(1):42-7.
2000: Borg A; Isola J; Chen J; Rubio C; Johansson U; Werelius B; Lindblom A
Germline BRCA1 and HMLH1 mutations in a family with male and female breast carcinoma.
International journal of cancer. Journal international du cancer 2000;85(6):796-800.
1999: Jernström H C; Johannsson O T; Loman N; Borg A; Olsson H
Reproductive factors in hereditary breast cancer.
Breast cancer research and treatment 1999;58(3):295-301.
1999: Møller P; Evans G; Haites N; Vasen H; Reis M M; Anderson E; Apold J; Hodgson S; Eccles D; Olsson H; Stoppa-Lyonnet D; Chang-Claude J; Morrison P J; Bevilacqua G; Heimdal K; Maehle L; Lalloo F; Gregory H; Preece P; Borg A; Nevin N C; Caligo M; Steel C M
Guidelines for follow-up of women at high risk for inherited breast cancer: consensus statement from the Biomed 2 Demonstration Programme on Inherited Breast Cancer.
Disease markers 1999;15(1-3):207-11.
1999: Borg A; Dørum A; Heimdal K; Maehle L; Hovig E; Møller P
BRCA1 1675delA and 1135insA account for one third of Norwegian familial breast-ovarian cancer and are associated with later disease onset than less frequent mutations.
Disease markers 1999;15(1-3):79-84.
1999: Planck M; Koul A; Fernebro E; Borg A; Kristoffersson U; Olsson H; Wenngren E; Mangell P; Nilbert M
hMLH1, hMSH2 and hMSH6 mutations in hereditary non-polyposis colorectal cancer families from southern Sweden.
International journal of cancer. Journal international du cancer 1999;83(2):197-202.
1999: Johannsson O; Loman N; Möller T; Kristoffersson U; Borg A; Olsson H
Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germline mutation carriers.
European journal of cancer (Oxford, England : 1990) 1999;35(8):1248-57.
1999: Fioretos T; Strömbeck B; Sandberg T; Johansson B; Billström R; Borg A; Nilsson P G; Van Den Berghe H; Hagemeijer A; Mitelman F; Höglund M
Isochromosome 17q in blast crisis of chronic myeloid leukemia and in other hematologic malignancies is the result of clustered breakpoints in 17p11 and is not associated with coding TP53 mutations.
Blood 1999;94(1):225-32.
1999: Laake K; Launonen V; Niederacher D; Gudlaugsdottir S; Seitz S; Rio P; Champème M H; Bièche I; Birnbaum D; White G; Sztan M; Sever N; Plummer S; Osorio A; Broeks A; Huusko P; Spurr N; Borg A; Cleton-Jansen A M; van't Veer L; Benitez J; Casey G; Peterlin B; Olah E; Børresen-Dale A L
Loss of heterozygosity at 11q23.1 and survival in breast cancer: results of a large European study. Breast Cancer Somatic Genetics Consortium.
Genes, chromosomes & cancer 1999;25(3):212-21.
1999: Nilbert M; Planck M; Fernebro E; Borg A; Johnson A
Microsatellite instability is rare in rectal carcinomas and signifies hereditary cancer.
European journal of cancer (Oxford, England : 1990) 1999;35(6):942-5.
1999: Nupponen N N; Porkka K; Kakkola L; Tanner M; Persson K; Borg A; Isola J; Visakorpi T
Amplification and overexpression of p40 subunit of eukaryotic translation initiation factor 3 in breast and prostate cancer.
The American journal of pathology 1999;154(6):1777-83.
1999: Persson K; Pandis N; Mertens F; Borg A; Baldetorp B; Killander D; Isola J
Chromosomal aberrations in breast cancer: a comparison between cytogenetics and comparative genomic hybridization.
Genes, chromosomes & cancer 1999;25(2):115-22.
1999: Koul A; Nilbert M; Borg A
A somatic BRCA2 mutation in RER+ endometrial carcinomas that specifically deletes the amino-terminal transactivation domain.
Genes, chromosomes & cancer 1999;24(3):207-12.
1999: Tirkkonen M; Kainu T; Loman N; Jóhannsson O T; Olsson H; Barkardóttir R B; Kallioniemi O P; Borg A
Somatic genetic alterations in BRCA2-associated and sporadic male breast cancer.
Genes, chromosomes & cancer 1999;24(1):56-61.
1998: Johannsson O; Loman N; Borg A; Olsson H
Pregnancy-associated breast cancer in BRCA1 and BRCA2 germline mutation carriers.
Lancet 1998;352(9137):1359-60.
1998: Mineta H; Borg A; Dictor M; Wahlberg P; Akervall J; Wennerberg J
p53 mutation, but not p53 overexpression, correlates with survival in head and neck squamous cell carcinoma.
British journal of cancer 1998;78(8):1084-90.
1998: Loman N; Johannsson O; Bendahl P O; Borg A; Fernö M; Olsson H
Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes.
Cancer 1998;83(2):310-9.
1998: Tanner M M; Karhu R A; Nupponen N N; Borg A; Baldetorp B; Pejovic T; Fernö M; Killander D; Isola J J
Genetic aberrations in hypodiploid breast cancer: frequent loss of chromosome 4 and amplification of cyclin D1 oncogene.
The American journal of pathology 1998;153(1):191-9.
1998: Neuhausen S L; Godwin A K; Gershoni-Baruch R; Schubert E; Garber J; Stoppa-Lyonnet D; Olah E; Csokay B; Serova O; Lalloo F; Osorio A; Stratton M; Offit K; Boyd J; Caligo M A; Scott R J; Schofield A; Teugels E; Schwab M; Cannon-Albright L; Bishop T; Easton D; Benitez J; King M C; Ponder B A; Weber B; Devilee P; Borg A; Narod S A; Goldgar D
Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study.
American journal of human genetics 1998;62(6):1381-8.
1998: Haraldsson K; Loman N; Zhang Q X; Johannsson O; Olsson H; Borg A
BRCA2 germ-line mutations are frequent in male breast cancer patients without a family history of the disease.
Cancer research 1998;58(7):1367-71.
1998: Phelan C M; Borg A; Cuny M; Crichton D N; Baldersson T; Andersen T I; Caligo M A; Lidereau R; Lindblom A; Seitz S; Kelsell D; Hamann U; Rio P; Thorlacius S; Papp J; Olah E; Ponder B; Bignon Y J; Scherneck S; Barkardottir R; Borresen-Dale A L; Eyfjörd J; Theillet C; Thompson A M; Larsson C
Consortium study on 1280 breast carcinomas: allelic loss on chromosome 17 targets subregions associated with family history and clinical parameters.
Cancer research 1998;58(5):1004-12.
1998: Jernström H; Johannsson O; Borg A; Ivarsson H; Olsson H
BRCA1-positive patients are small for gestational age compared with their unaffected relatives.
European journal of cancer (Oxford, England : 1990) 1998;34(3):368-71.
1998: Jóhannsson O T; Ranstam J; Borg A; Olsson H
Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(2):397-404.
1998: Bergthorsson J T; Jonasdottir A; Johannesdottir G; Arason A; Egilsson V; Gayther S; Borg A; Hakanson S; Ingvarsson S; Barkardottir R B
Identification of a novel splice-site mutation of the BRCA1 gene in two breast cancer families: screening reveals low frequency in Icelandic breast cancer patients.
Human mutation 1998;Suppl 1():S195-7.
1997: Koul A; Borg A; Pejovic T; Bendahl P O; Högberg T; Iosif C S; Killander D
Identification of TP53 gene mutations in uterine corpus cancer with short follow-up.
Gynecologic oncology 1997;67(3):295-302.
1997: Hedenfalk I A; Baldetorp B; Borg A; Oredsson S M
Activated cell cycle checkpoints in epirubicin-treated breast cancer cells studied by BrdUrd-flow cytometry.
Cytometry 1997;29(4):321-7.
1997: Jernström H C; Olsson H; Borg A
Reduced testosterone, 17 beta-oestradiol and sexual hormone binding globulin, and increased insulin-like growth factor-1 concentrations, in healthy nulligravid women aged 19-25 years who were first and/or second degree relatives to breast cancer patients.
European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 1997;6(4):330-40.
1997: Håkansson S; Johannsson O; Johansson U; Sellberg G; Loman N; Gerdes A M; Holmberg E; Dahl N; Pandis N; Kristoffersson U; Olsson H; Borg A
Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer.
American journal of human genetics 1997;60(5):1068-78.
1997: Johannsson O; Ranstam J; Borg A; Olsson H
BRCA1 mutations and survival in women with ovarian cancer.
The New England journal of medicine 1997;336(17):1255-6; author reply 1256-7.
1997: Zhang Q X; Borg A; Wolf D M; Oesterreich S; Fuqua S A
An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer.
Cancer research 1997;57(7):1244-9.
1997: Tirkkonen M; Johannsson O; Agnarsson B A; Olsson H; Ingvarsson S; Karhu R; Tanner M; Isola J; Barkardottir R B; Borg A; Kallioniemi O P
Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations.
Cancer research 1997;57(7):1222-7.
1997: Jóhannsson O T; Idvall I; Anderson C; Borg A; Barkardóttir R B; Egilsson V; Olsson H
Tumour biological features of BRCA1-induced breast and ovarian cancer.
European journal of cancer (Oxford, England : 1990) 1997;33(3):362-71.
1997: Devilee P; Hermans J; Eyfjörd J; Bøorresen A L; Lidereau R; Sobol H; Borg A; Cleton-Jansen A M; Oláh E; Cohen B B; Scherneck S; Hamann U; Peterlin B; Caligo M; Bignon Y J; Maugard C
Loss of heterozygosity at 7q31 in breast cancer: results from an International Collaborative Study Group. The Breast Cancer Somatic Genetics Consortium.
Genes, chromosomes & cancer 1997;18(3):193-9.
1997: Mineta H; Borg A; Dictor M; Wahlberg P; Wennerberg J
Correlation between p53 mutation and cyclin D1 amplification in had and neck squamous cell carcinoma.
Oral oncology 1997;33(1):42-6.
1997: Akervall J A; Michalides R J; Mineta H; Balm A; Borg A; Dictor M R; Jin Y; Loftus B; Mertens F; Wennerberg J P
Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression.
Cancer 1997;79(2):380-9.
1996: Zhang Q X; Hilsenbeck S G; Fuqua S A; Borg A
Multiple splicing variants of the estrogen receptor are present in individual human breast tumors.
The Journal of steroid biochemistry and molecular biology 1996;59(3-4):251-60.
1996: van den Berg J; Johannsson O; Håkansson S; Olsson H; Borg A
Allelic loss at chromosome 13q12-q13 is associated with poor prognosis in familial and sporadic breast cancer.
British journal of cancer 1996;74(10):1615-9.
1996: Panagopoulos I; Pandis N; Thelin S; Petersson C; Mertens F; Borg A; Kristoffersson U; Mitelman F; Aman P
The FHIT and PTPRG genes are deleted in benign proliferative breast disease associated with familial breast cancer and cytogenetic rearrangements of chromosome band 3p14.
Cancer research 1996;56(21):4871-5.
1996: Johannesdottir G; Gudmundsson J; Bergthorsson J T; Arason A; Agnarsson B A; Eiriksdottir G; Johannsson O T; Borg A; Ingvarsson S; Easton D F; Egilsson V; Barkardottir R B
High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients.
Cancer research 1996;56(16):3663-5.
1996: Petersson C; Pandis N; Mertens F; Adeyinka A; Ingvar C; Ringberg A; Idvall I; Bondeson L; Borg A; Olsson H; Kristoffersson U; Mitelman F
Chromosome aberrations in prophylactic mastectomies from women belonging to breast cancer families.
Genes, chromosomes & cancer 1996;16(3):185-8.
1996: Sun X F; Johannsson O; Håkansson S; Sellberg G; Nordenskjöld B; Olsson H; Borg A
A novel p53 germline alteration identified in a late onset breast cancer kindred.
Oncogene 1996;13(2):407-11.
1996: Borg A; Johannsson U; Johannsson O; Häkansson S; Westerdahl J; Mäsbäck A; Olsson H; Ingvar C
Novel germline p16 mutation in familial malignant melanoma in southern Sweden.
Cancer research 1996;56(11):2497-500.
1996: Fernö M; Bendahl P O; Borg A; Brundell J; Hirschberg L; Olsson H; Killander D
Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay.
European journal of cancer (Oxford, England : 1990) 1996;32A(5):793-801.
1996: Johannsson O; Ostermeyer E A; Håkansson S; Friedman L S; Johansson U; Sellberg G; Brøndum-Nielsen K; Sele V; Olsson H; King M C; Borg A
Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden.
American journal of human genetics 1996;58(3):441-50.
1996: Olsson H; Borg A
Genetic predisposition to breast cancer.
Acta oncologica (Stockholm, Sweden) 1996;35(1):1-8.
1995: Jönsson M; Johannsson O; Borg A
Infrequent occurrence of microsatellite instability in sporadic and familial breast cancer.
European journal of cancer (Oxford, England : 1990) 1995;31A(13-14):2330-4.
1995: Børresen A L; Andersen T I; Eyfjörd J E; Cornelis R S; Thorlacius S; Borg A; Johansson U; Theillet C; Scherneck S; Hartman S
TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains.
Genes, chromosomes & cancer 1995;14(1):71-5.
1995: Borg A; Lennerstrand J; Stenmark-Askmalm M; Fernö M; Brisfors A; Ohrvik A; Stål O; Killander D; Lane D; Brundell J
Prognostic significance of p53 overexpression in primary breast cancer; a novel luminometric immunoassay applicable on steroid receptor cytosols.
British journal of cancer 1995;71(5):1013-7.
1995: Fernö M; Baldetorp B; Bendahl P O; Borg A; Ewers S B; Olsson H; Rydén S; Sigurdsson H; Killander D
Recurrence-free survival in breast cancer improved by adjuvant tamoxifen--especially for progesterone receptor positive tumors with a high proliferation.
Breast cancer research and treatment 1995;36(1):23-34.
1994: Jónsson A; Borg A; Hannesson P; Herrlin K; Jonsson K; Sloth M; Petterson H
Film-screen vs. digital radiography in rheumatoid arthritis of the hand. An ROC analysis.
Acta radiologica (Stockholm, Sweden : 1987) 1994;35(4):311-8.
1994: Borg A; Baldetorp B; Fernö M; Killander D; Olsson H; Rydén S; Sigurdsson H
ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer.
Cancer letters 1994;81(2):137-44.
1994: Borg A; Zhang Q X; Johannsson O; Olsson H
High frequency of allelic imbalance at the BRCA1 region on chromosome 17q in both familial and sporadic ductal breast carcinomas.
Journal of the National Cancer Institute 1994;86(10):792-4.
1994: Fernö M; Baldetorp B; Borg A; Brouillet J P; Olsson H; Rochefort H; Sellberg G; Sigurdsson H; Killander D
Cathepsin D, both a prognostic factor and a predictive factor for the effect of adjuvant tamoxifen in breast cancer. South Sweden Breast Cancer Group.
European journal of cancer (Oxford, England : 1990) 1994;30A(14):2042-8.
1994: Jarlman O; Borg A; Braw M; Kehler M; Lyttkens K; Samuelsson L
Breast imaging: a comparison of digital luminescence radiographs displayed on TV-monitor and film-screen mammography.
Cancer detection and prevention 1994;18(5):375-81.
1993: Zhang Q X; Borg A; Fuqua S A
An exon 5 deletion variant of the estrogen receptor frequently coexpressed with wild-type estrogen receptor in human breast cancer.
Cancer research 1993;53(24):5882-4.
1992: Borg A; Zhang Q X; Olsson H; Wenngren E
Chromosome 1 alterations in breast cancer: allelic loss on 1p and 1q is related to lymphogenic metastases and poor prognosis.
Genes, chromosomes & cancer 1992;5(4):311-20.
1992: Borg A; Baldetorp B; Fernö M; Olsson H; Sigurdsson H
c-myc amplification is an independent prognostic factor in postmenopausal breast cancer.
International journal of cancer. Journal international du cancer 1992;51(5):687-91.
1992: Borg A; Zhang Q X; Alm P; Olsson H; Sellberg G
The retinoblastoma gene in breast cancer: allele loss is not correlated with loss of gene protein expression.
Cancer research 1992;52(10):2991-4.
1992: Ewers S B; Attewell R; Baldetorp B; Borg A; Långström E; Killander D
Prognostic potential of flow cytometric S-phase and ploidy prospectively determined in primary breast carcinomas.
Breast cancer research and treatment 1992;20(2):93-108.
1992: Ewers S B; Attewell R; Baldetorp B; Borg A; Fernö M; Långström E; Killander D
Prognostic significance of flow cytometric DNA analysis and estrogen receptor content in breast carcinomas--a 10 year survival study.
Breast cancer research and treatment 1992;24(2):115-26.
1992: Fernö M; Baldetorp B; Borg A; Olsson H; Sigurdsson H; Killander D
Flow cytometric DNA index and S-phase fraction in breast cancer in relation to other prognostic variables and to clinical outcome.
Acta oncologica (Stockholm, Sweden) 1992;31(2):157-65.
1992: Ewers S B; Attewell R; Baldetorp B; Borg A; Fernö M; Långström E; Rydén S; Killander D
Flow cytometry DNA analysis and prediction of loco-regional recurrences after mastectomy in breast cancer.
Acta oncologica (Stockholm, Sweden) 1992;31(7):733-40.
1991: Olsson H; Borg A; Fernö M; Ranstam J; Sigurdsson H
Her-2/neu and INT2 proto-oncogene amplification in malignant breast tumors in relation to reproductive factors and exposure to exogenous hormones.
Journal of the National Cancer Institute 1991;83(20):1483-7.
1991: Borg A; Sigurdsson H; Clark G M; Fernö M; Fuqua S A; Olsson H; Killander D; McGurie W L
Association of INT2/HST1 coamplification in primary breast cancer with hormone-dependent phenotype and poor prognosis.
British journal of cancer 1991;63(1):136-42.
1991: Borg A; Baldetorp B; Fernö M; Killander D; Olsson H; Sigurdsson H
ERBB2 amplification in breast cancer with a high rate of proliferation.
Oncogene 1991;6(1):137-43.
1991: Olsson H; Borg A; Fernö M; Möller T R; Ranstam J
Early oral contraceptive use and premenopausal breast cancer--a review of studies performed in southern Sweden.
Cancer detection and prevention 1991;15(4):265-71.
1990: Sigurdsson H; Baldetorp B; Borg A; Dalberg M; Fernö M; Killander D; Olsson H; Ranstam J
Flow cytometry in primary breast cancer: improving the prognostic value of the fraction of cells in the S-phase by optimal categorisation of cut-off levels.
British journal of cancer 1990;62(5):786-90.
1990: Borg A; Tandon A K; Sigurdsson H; Clark G M; Fernö M; Fuqua S A; Killander D; McGuire W L
HER-2/neu amplification predicts poor survival in node-positive breast cancer.
Cancer research 1990;50(14):4332-7.
1990: Sigurdsson H; Baldetorp B; Borg A; Dalberg M; Fernö M; Killander D; Olsson H
Indicators of prognosis in node-negative breast cancer.
The New England journal of medicine 1990;322(15):1045-53.
1990: Fernö M; Borg A; Johansson U; Norgren A; Olsson H; Rydén S; Sellberg G
Estrogen and progesterone receptor analyses in more than 4,000 human breast cancer samples. A study with special reference to age at diagnosis and stability of analyses. Southern Swedish Breast Cancer Study Group.
Acta oncologica (Stockholm, Sweden) 1990;29(2):129-35.
1989: Fernö M; Borg A; Horvath G; Lindahl B
Enzyme immunoassay of progesterone receptor in cancerous and normal endometrial tissue. A comparison with dextran coated charcoal method.
Anticancer research 1989;9(6):1681-3.
1989: Borg A; Linell F; Idvall I; Johansson S; Sigurdsson H; Fernö M; Killander D
HER2/neu amplification and comedo type breast carcinoma.
Lancet 1989;1(8649):1268-9.
1989: Borg A; Fernö M; Idvall I
Estrogen receptor enzyme immunoassay in fine-needle aspirates from human breast cancer.
Acta oncologica (Stockholm, Sweden) 1989;28(2):187-91.
1989: Fernö M; Borg A; Johansson U
Enzyme immunoassay of progesterone receptor in breast cancer biopsy samples. A comparison with the dextran coated charcoal method.
Acta oncologica (Stockholm, Sweden) 1989;28(1):19-22.
1988: Rydén S; Fernö M; Borg A; Hafström L; Möller T; Norgren A
Prognostic significance of estrogen and progesterone receptors in stage II breast cancer.
Journal of surgical oncology 1988;37(4):221-6.
1988: Olsson H; Möller T R; Ranstam J; Borg A; Fernö M
Early oral contraceptive use as a prognostic factor in breast cancer.
Anticancer research 1988;8(1):29-32.
1987: Fernö M; Borg A; Idvall I
Estramustine binding site in human breast cancer biopsy samples. Its relation to estrogen and progesterone receptor levels, age and menopausal status.
European journal of cancer & clinical oncology 1987;23(10):1505-10.
1987: Olsson H; Lindahl B; Ranstam J; Borg A; Fernö M; Norgren A
Permanent alterations induced in plasma prolactin and estrogen receptor concentration in benign and malignant tissue of women who started oral contraceptive use at an early age.
Anticancer research 1987;7(4B):853-6.
1987: Fernö M; Borg A; Ingvar C; Jönsson P E
Estrogen receptor and binding site for estramustine in metastatic malignant melanoma.
Anticancer research 1987;7(4B):741-3.
1986: Fernö M; Borg A; Sellberg G
Enzyme immuno assay of the estrogen receptor in breast cancer biopsy samples. A comparison with isoelectric focusing.
Acta radiologica. Oncology 1986;25(3):171-5.
1986: Olsson H; Borg A; Ewers S B; Fernö M; Möller T; Ranstam J
A biological marker, strongly associated with early oral contraceptive use, for the selection of a high risk group for premenopausal breast cancer.
Medical oncology and tumor pharmacotherapy 1986;3(2):77-81.
1982: Norgren A; Borg A; Fernö M; Johansson U; Lindahl B; Tsiobanelis K
Improved method for assay of estradiol and progesterone receptors with special reference to breast cancer.
Anticancer research 1982;2(5):315-20.
1982: Lindahl B; Alm P; Borg A; Fernö M; Grundsell H; Johnsson J E; Norgren A; Tropé C
Correlation between estradiol-17 beta and progesterone cytosol receptor concentration, histologic differentiation and 3H-thymidine incorporation in endometrial carcinoma.
Anticancer research 1982;2(4):203-7.

Sign-in to see more